Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) Conference call today at 8:30 a.m. ET GlobeNewswire October 27, 2025 CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily […]

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market GlobeNewswire October 27, 2025 MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced

MicrobiotiX Receives IND Approval for Novel Bacteriophage Drug MP101 Korea's First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in Patients with Acute Pneumonia GlobeNewswire October 27, 2025 SEOUL, South Korea, Oct. 27, 2025 (GLOBE NEWSWIRE) — MicrobiotiX Co., Ltd. (CEO Dongeun Yong), a company specializing

Blaqclouds Executes Blockchain Partnership with Super Studios USA, Led by Former Ridley Scott & Associates Executive Producer Developing a Billion-Dollar Entertainment Complex in Texas GlobeNewswire October 27, 2025 ROBESONIA, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) — Blaqclouds, Inc. (OTC: BCDS), a leading Web3 infrastructure and decentralized finance company, today announced it has entered into a

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call – Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025 GlobeNewswire October 27, 2025 CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people

Baxter International Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – BAX GlobeNewswire October 27, 2025 LOS ANGELES, Oct. 27, 2025 (GLOBE NEWSWIRE) — The DJS Law Group reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations

Telesat schedules third quarter 2025 earnings conference call for November 4, 2025 GlobeNewswire October 27, 2025 OTTAWA, Oct. 27, 2025 (GLOBE NEWSWIRE) — Telesat (Nasdaq and TSX: TSAT), one of the world's largest and most innovative satellite operators, has scheduled a conference call on Tuesday, November 4, 2025, at 10:30 a.m. EST to discuss its

Abaxx Exchange Integrates with TradingView, Extending LNG and Singapore Gold Futures Contract Liquidity to 100M+ Users Integration adds the world's only physically-backed LNG forward curves and Singapore Gold Kilobar Futures to TradingView, making new regional benchmarks accessible for global price discovery GlobeNewswire October 27, 2025 TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc.

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers GlobeNewswire October 27, 2025 Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term shareholder value BURLINGTON, Mass. and JERUSALEM, Oct. 27, 2025 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or

Patent covers active pharmaceutical ingredient with protection until 2041 Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and Trademark Office (USPTO) has granted a patent for the active pharmaceutical ingredient (API) in its lead candidate for atopic dermatitis (AD). The patent complements Alphyn's previously issued U.S. patent protecting